英夫利昔单抗在IVIG无应答川崎病中的应用研究进展

doi:10.12372/jcp.2025.24e1214

Abstract

Abstract:

This review aims to systematically evaluate the therapeutic role of infliximab in patients with Kawasaki disease (KD) who are resistant to intravenous immunoglobulin (IVIG), with a focus on its mechanism of action, clinical efficacy, and safety profile. By synthesizing recent advances in both domestic and international research, we provide a comprehensive assessment of the benefits and current limitations of infliximab therapy. Evidence indicates that infliximab significantly shortens fever duration, reduces levels of inflammatory biomarkers, and lowers the risk of coronary artery lesions. As understanding of the etiology and immunopathogenesis of KD continues to evolve, infliximab is emerging as a promising therapeutic option for IVIG-resistant cases. This review highlights its potential to inform optimized clinical management strategies and improve long-term outcomes in affected patients.

Key words: infliximab, intravenous immunoglobulin, Kawasaki disease, clinical efficacy, child

CLC Number:

FENG Xiwei, GONG Fangqi. Progress on the application of infliximab in IVIG-resistant Kawasaki disease[J].Journal of Clinical Pediatrics, 2025, 43(11): 878-882.

References 31

[1]	Newburger JW, Takahashi M, Burns JC. Kawasaki disease[J]. J Am Coll Cardanol, 2016, 67(14): 1738-1749.
[2]	Burns JC. The etiologies of Kawasaki disease[J]. J Clin Invest, 2024, 134(5): e176938.
[3]	Agarwal S, Agrawal DK. Kawasaki disease: etiopathogenesis and novel treatment strategies[J]. Expert Rev Clin Immunol, 2017, 13(3): 247-258.
[4]	McCrindle BW, Rowley AH, Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association[J]. Circulation, 2017, 135(17): e927-e999.
[5]	Tremoulet AH, Jain S, Jaggi P, et al. Infliximab for intensification of primary therapy for Kawasaki disease: a phase 3 randomised, double-blind, placebo-controlled trial[J]. Lancet, 2014, 383(9930): 1731-1738. doi: 10.1016/S0140-6736(13)62298-9 pmid: 24572997
[6]	Chen J, Liao J, Xiang L et al. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review[J]. Front Immunol, 2023, 14: 1237670.
[7]	Burns JC, Roberts SC, Tremoulet AH, et al. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial[J]. Lancet Child Adolesc Health, 2021, 5(12): 852-861.
[8]	Wang L, He M, Wang W, et al. Efficacy and safety of infliximab in the treatment of Kawasaki disease: a systematic review and meta-analysis[J]. Eur J Pediatr, 2024, 183(4):1765-1776.
[9]	Cole LD, Osborne CM, Silveira LJ, et al. IVIG compared with IVIG plus infliximab in multisystem inflammatory syndrome in children[J]. Pediatrics, 2021, 148(6): e2021052702.
[10]	Miura M, Kobayashi T, Igarashi T, et al. Real-world safety and effectiveness of infliximab in pediatric patients with acute Kawasaki disease: a postmarketing surveillance in Japan (SAKURA Study)[J]. Pediatr Infect Dis J, 2020, 39(1): 41-47. doi: 10.1097/INF.0000000000002503 pmid: 31815838
[11]	Onouchi Y, Suzuki Y, Suzuki H, et al. ITPKC and CASP3 polymorphisms and risks for IVIG unresponsiveness and coronary artery lesion formation in Kawasaki disease[J]. Pharmacogenomics J, 2013, 13(1):52-59. doi: 10.1038/tpj.2011.45 pmid: 21987091
[12]	董明星, 王喜霞, 焦富勇, 等. 川崎病基因多态性的研究进展[J]. 中国当代儿科杂志, 2023, 25(12): 1234-1238.
	Dong MX, Wang XX, Jiao FY, et al. Research advances in genetic polymorphisms in Kawasaki disease[J]. Zhongguo Dangdai Erke Zazhi, 2023, 25(12): 1234-1238.
[13]	Ye Q, Gong FQ, Shang SQ, et al. Intravenous immunoglobulin treatment responsiveness depends on the degree of CD8⁺T cell activation in Kawasaki disease[J]. Clin Immunol, 2016, 171(10): 25-31.
[14]	胡珊, 王永清. 川崎病外周血淋巴细胞与T细胞亚群的相关性分析[J]. 当代医学, 2015, 21(29): 1-3.
	Hu S, Wang YQ. Correlation analysis of peripheral blood lymphocytes and T cell subsets in Kawasaki disease[J]. Dangdai Yixue, 2015, 21(29): 1-3.
[15]	Noval Rivas M, Arditi M. Kawasaki disease: pathophysiology and insights from mouse models[J]. Nat Rev Rheumatol, 16(7): 391-405
[16]	Ohnishi Y, Okada S, Kawakami-Miyake A, et al. Safety and feasibility of infliximab therapy in children with Kawasaki disease who received live vaccinations[J]. Pediatr Infect Dis J, 2022, 41(9): e388-e392.
[17]	Alexander H. Sprague, Raouf A. Inflammatory cytokines in vascular dysfunction and vascular disease[J]. Biochem Pharmacol, 2009, 78(6): 539-552 doi: 10.1016/j.bcp.2009.04.029 pmid: 19413999
[18]	Hachiya A, Kobayashi N, Matsuzaki S, et al. Analysis of biomarker serum levels in IVIG and infliximab refractory Kawasaki disease patients[J]. Clin Rheumatol, 2018, 37(7):1937-1943. doi: 10.1007/s10067-017-3952-7 pmid: 29302828
[19]	Wardle AJ, Connolly GM, Seager MJ, et al. Corticosteroids for the treatment of Kawasaki disease in children[J]. Cochrane Database Syst Rev, 2017, 1(1): CD011188.
[20]	Li D, Li X, Dou W, et al. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis[J]. Transl Pediatr, 2021, 10(5): 1294-1306. doi: 10.21037/tp-20-482 pmid: 34189087
[21]	宋木雯. 英夫利昔单抗治疗IVIG无反应型川崎病的META分析[D]. 重庆医科大学, 2020.
	Song MW. Meta-analysis of infliximab treatment for IVIG-resistant Kawasaki disease[D]. Chongqing Medical University, 2020.
[22]	彭宇, 刘小惠, 欧阳倩, 等. 免疫球蛋白无应答川崎病再次免疫球蛋白/英夫利昔单抗和激素治疗队列研究[J]. 中国循证儿科杂志, 2022, 17(1): 35-38.
	Peng Y, Liu XH, Ouyang Q, et al. Treatment of refractory Kawasaki disease with IVIG, infliximab or corticosteroids: a cohort study[J]. Zhongguo Xunzheng Erke Zazhi, 2022, 17(1): 35-38.
[23]	颜凯, 林平, 尧战勇. 英夫利昔单抗联合阿托伐他汀治疗川崎病效果及对患儿血清NT-proBNP、iNOS影响[J]. 临床误诊误治, 2022, 35(3): 36-39.
	Yan K, Lin P, Yao ZY. Efficacy of infliximab combined with atorvastatin in the treatment of Kawasaki disease and its effects on serum NT-proBNP and iNOS in children[J]. Linchuang Wuzhen Wuzhi, 2022, 35(3): 36-39.
[24]	Lichtenstein L, Ron Y, Kivity S, et al. Infliximab-related infusion reactions: systematic review[J]. J Crohns Colitis, 2015, 9(9): 806-815. doi: 10.1093/ecco-jcc/jjv096 pmid: 26092578
[25]	Antonio JR, Sanmiguel J, Cagnon GV, et al. Infliximab in patients with psoriasis and other inflammatory diseases: evaluation of adverse events in the treatment of 168 patients[J]. An Bras Dermatol, 2016, 91(3): 306-310. doi: 10.1590/abd1806-4841.20164292 pmid: 27438197
[26]	Sapountzi E, Fidani L, Giannopoulos A, et al. Association of genetic polymorphisms in Kawasaki disease with the response to intravenous immunoglobulin therapy[J]. Pediatr Cardiol, 2023, 44(1): 1-12.
[27]	黄敏. 单细胞测序技术在川崎病研究中的应用现状[J]. 临床儿科杂志, 2023, 41(7): 481-485.
	Huang M. Application of single cell sequencing technology in Kawasaki disease research[J]. Linchuang Erke Zazhi, 2023, 41(7): 481-485.
[28]	Rahman P, Baer P, Keystone E, et al. Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry[J]. BMC Rheumatol, 2020, 4: 46. doi: 10.1186/s41927-020-00145-4 pmid: 32968710
[29]	Xie LP, Zhao L, Chu C, et al. Retrospective analysis of infliximab in the treatment of Kawasaki disease[J]. Zhonghua Erke Zazhi, 2022, 60(1): 14-19.
[30]	Masuda H, Kobayashi T, Hachiya A, et al. Infliximab for the treatment of refractory Kawasaki disease: a nationwide survey in Japan[J]. J Pediatr, 2018, 195: 115-120.
[31]	Hur G, Song MS, Sohn S, et al. Infliximab treatment for intravenous immunoglobulin-resistant Kawasaki disease: a multicenter study in Korea[J]. Korean Circ J, 2019, 49(2): 183-191. doi: 10.4070/kcj.2018.0214 pmid: 30468032

Progress on the application of infliximab in IVIG-resistant Kawasaki disease

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LIN Jinfeng, CHEN Yi, DENG Yan, FENG Ai, HUANG Juan, CHEN Lizhu, XIE Jingqi, NIE Xiaojing. A comparative study on the detection of anti-Nephrin antibodies in children's nephrotic syndrome by chemiluminescence method and cell-based assay [J]. Journal of Clinical Pediatrics, 2026, 44(8): 682-689.
[2]	ZHENG Fangyuan, WANG Miao, DING Mingming, LU Aidong, JIA Yueping, ZENG Huimin, ZHANG Leping. Next-generation sequencing identified gene variants and their prognostic impact in pediatric Philadelphia chromosome positive acute lymphoblastic leukemia [J]. Journal of Clinical Pediatrics, 2026, 44(8): 690-697.
[3]	ZHANG Xiao, FANG Hongjun, KUANG Xiaojun, WANG Lijuan, WU Zhao, JIANG Sha, LI Pei, WU Liwen. Analysis of the clinical and electrophysiological characteristics of atonic seizures in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 698-704.
[4]	WANG Mengqian, YANG Hui. Case series analysis of 13 intestinal Behcet’s syndrome in children [J]. Journal of Clinical Pediatrics, 2026, 44(8): 705-711.
[5]	WU Xirong, GAO Qi, GUO Siyuan, YIN Qingqin, QIN Qiang, YIN Ju, JIAO Anxia, CHEN Chenghao, WU Di, WANG Bei, DUAN Xiaomin, PENG Yun, XU Baoping, GAO Liwei. Clinical characteristics and prognosis of pulmonary mucormycosis in children with diabetes mellitus [J]. Journal of Clinical Pediatrics, 2026, 44(8): 712-720.
[6]	HAN Yanan, GE Lanlan, CUI Jieyuan. A case report of branchio-oto-renal syndrome caused by EYA1 gene variant with a 6-year follow-up [J]. Journal of Clinical Pediatrics, 2026, 44(8): 721-726.
[7]	SHI Jiayi, GAO Chunlin, JIA Lili, LU Yunyun, SUN Tao, ZHU Xiaodong, XIA Zhengkun, ZHANG Pei. Phenotypic characteristics and prognostic analysis of a pedigree with childhood isolated nephrotic syndrome caused by compound heterozygous mutations in the COQ2 gene [J]. Journal of Clinical Pediatrics, 2026, 44(8): 727-732.
[8]	Rachel Rosen, Osvaldo Borrelli, Christophe Faure, Katja Karrento, Usha Krishnan, Samuel Nurko, Nathalie Rommel, Alan Silverman, Michiel van Wijk, Marc Benninga (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: upper gastrointestinal disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 595-608.
[9]	Carlo Di Lorenzo, Miguel Saps, Bruno P. Chumpitazi, Shaman Rajindrajith, Annamaria Staiano, Nikhil Thapar, Miranda van Tilburg, Carlos Velasco-Benítez, Arine Vlieger (Author), Chinese Medical Association Parenteral and Enteral Nutrition Branch Pediatrics Group, The Subspecialty Group of Gastroenterology, The Society of Pediatric, Chinese Medical Association, Gastroenterology Group, Pediatrician Branch, Chinese Medical Doctor Association (Translator). Core interpretation and explanation of Rome Ⅴ diagnostic criteria: lower and biliary disorders of gut-brain interaction in children and adolescents [J]. Journal of Clinical Pediatrics, 2026, 44(7): 609-621.
[10]	LI Xufeng, TANG Haoxun, LI Xingjun, ZHANG Lize, GAO Chenqing, ZHAO Shunying, LIU Jianhua. Clinical characteristics, chest CT imaging phenotypes, and their correlation with prognosis in 76 children with Chlamydia pneumoniae pneumonia [J]. Journal of Clinical Pediatrics, 2026, 44(7): 622-627.
[11]	WANG Zhen, SHAO Jingbo, ZHANG Na, XIA Min, ZHU Jiashi, DU Chengkan, LI Hong. Factors influencing long-term recurrence in pediatric acute lymphoblastic leukemia patients with low-risk disease at initial diagnosis: a five-year follow-up analysis of 254 cases from a single center [J]. Journal of Clinical Pediatrics, 2026, 44(7): 628-635.
[12]	GUO Xuemei, XUE Yao, WANG Yongren, RONG Liucheng, FANG Yongjun, LIN Rufeng. Clinical features and prognosis of childhood acute myeloid leukemia with CBFA2T3::GLIS2 fusion [J]. Journal of Clinical Pediatrics, 2026, 44(7): 636-643.
[13]	YANG Lijun, FU Dongxia, CUI Yan, YANG Junmei, ZHANG Liming. Clinical manifestation and genetic analysis of CHARGE syndrome caused by CHD7 gene variation [J]. Journal of Clinical Pediatrics, 2026, 44(7): 644-650.
[14]	HU Yan, YANG Fan, LIANG Aimin, MAO Meng. Identification and management of faltering growth in children: insights from the 13th International Conference on Nutrition and Growth [J]. Journal of Clinical Pediatrics, 2026, 44(6): 485-488.
[15]	LIU Ziyao, WANG Congying, WANG Hongmao, ZHANG Mingming, XU Yingjie, LAI Jianming, NIU Wenquan, LI Xiaohui. Early differentiation of Kawasaki disease with joint symptoms and systemic juvenile idiopathic arthritis with Kawasaki disease-like symptoms: a single-center retrospective study [J]. Journal of Clinical Pediatrics, 2026, 44(6): 489-498.